Mission to International Space Station Launches Research on Brain Organoids, Heart Muscle Atrophy, and Cold Welding
The SpaceX CRS-31 mission to the ISS for NASA includes studies on in-space manufacturing, cardiac health, and a method to...
Cancer
Cosmos Health’s Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%
CHICAGO, IL / ACCESSWIRE / November 1, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing...
Nation’s Largest Pancreatic Cancer Early Detection Study Holds Annual Meeting in San Diego
PRECEDE Study Aims to Increase Early Detection in Pancreatic CancerSAN DIEGO, CA / ACCESSWIRE / November 1, 2024 / Pancreatic...
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company...
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
FemBloc issued patent provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth controlATLANTA, Nov. 01, 2024 (GLOBE...
Galecto Reports Third Quarter 2024 Financial Results
- Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420,...
Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
Bagsværd, Denmark, 1 November 2024 – Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE...
The MUHC Foundation and the Beat 92.5’s Raise Craze raises $95,000 to help strike out breast cancer
All funds are supporting breast cancer care at the McGill University Health Centre (MUHC) The MUHC Foundation and the Beat...
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a...
Invitation to Presentation of Cantargia’s Interim Report January – September 2024
LUND, SE / ACCESSWIRE / November 01, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) invites investors, analysts and...
SHASQI TO PRESENT AT WORLD ADC AND SITC CONFERENCES
SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi") a biotech company using in-vivo click chemistry to enable pre-targeting...
FormaPath demonstrate ‘mini’ nToto at CAP
FormaPath made a major unveiling with their exhibit at the 2024 College of American Pathologists Annual Meeting - a desktop...
HKUST Spearheads Four Large AI Models to Revolutionize Healthcare
HONG KONG, Oct. 31, 2024 /PRNewswire/ -- In a groundbreaking initiative, The Hong Kong University of Science and Technology (HKUST)...
Illumina to preview newest innovations in NGS and multiomic technologies at the American Society of Human Genetics Annual Meeting
New, groundbreaking technology delivers Illumina's most comprehensive genome yet; early results from Broad Clinical Labs demonstrate a highly simplified workflow,...
TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative
Cure51 plans to analyze more than 1,000 tumor samples from exceptional cancer survivors PARIS, Oct. 31, 2024 /PRNewswire/ -- French...
FluoSphera Expands Its Systemic Technology Platform to empower ADCs to meet their promise
GENEVA and BOSTON Oct. 31, 2024 /PRNewswire/ -- FluoSphera, the leader in systemic drug discovery, is excited to announce its strategic...
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
BASKING RIDGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative...
IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024
LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated...
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral presentation at SU2C Innovation Summit...